Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction

Journal of Neuroimmune Pharmacology

Volumn 8, Issue 5, 2013, Pages 1239-1250

  Robinson, Rebecca Hartzell ^a   Meissler, Joseph J ^a   Breslow Deckman, Jessica M ^b   Gaughan, John ^a   Adler, Martin W ^a   Eisenstein, Toby K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cannabinoid receptor 2; Cannabinoids; Immunosuppression; Mixed lymphocyte reaction; T cells

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CD3 ANTIBODY; DRONABINOL; INTERLEUKIN 2; O 1966; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IN VITRO STUDY; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SKIN TRANSPLANTATION; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; CANNABINOIDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; IN SITU NICK-END LABELING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 84891371881     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-013-9485-1     Document Type: Article

References (69)

1. Adhikary S, Li H, Heller J, Skarica M, Zhang M, Ganea D, Tuma RF (2011) Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury. J Neurotrauma 28:1-11. doi: 10.1089/neu.2011.1853
2. Adhikary S, Kocieda VP, Yen JH, Tuma RF, Ganea D (2012) Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood 120:3741-3749. doi: 10.1182/blood-2012-06-435362
3. Baty DE, Zhang M, Li H, Erb CJ, Adler MW, Ganea D, Loftus CM, Jallo JI, Tuma RF (2008) Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury. Clin Neurosurg 55:172-177. doi: 10.1227/01.neu.0000279910.45183.15
4. Borner C, Smida M, Hollt V, Schraven B, Kraus J (2009) Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem 284:35450-35460. doi: 10.1074/jbc.M109.006338
5. Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5:e8688. doi: 10.1371/journal.pone.0008688, Electronic Resource
6. Colvin-Adams M, Smith JM, Heubner BM, Skeans MA, Edwards LB, Waller C, Snyder JJ, Israni AK, Kasiske BL (2013) OPTN/SRTR 2011 annual data report: heart. Am J Transplant 13:119-148. doi: 10.1111/ajt.12023
7. Coopman K, Smith LD, Wright KL, Ward SG (2007) Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int Immunopharm 7:360-371. doi: 10.1016/j.intimp. 2006.11.008
8. Croxford JL, Yamamura T (2005) Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 166:3-18. doi: 10.1016/j.jneuroim.2005.04.023
9. Daaka Y, Friedman H, Klein TW (1996) Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 276:776-783
10. 9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol 189:17-22. doi: 10.1016/j.jneuroim.2007.06.001
11. Fraga D, Raborn ES, Ferreira GA, Cabral GA (2011) Cannabinoids inhibit migration of microglial-like cells to the HIV protein Tat. J Neuroimmune Pharmacol 6:566-577. doi: 10.1007/s11481-011-9291-6
12. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61. doi: 10.1111/j.1432-1033.1995.tb20780.x
13. Ghosh S, Preet A, Groopman JE, Ganju RK (2006) Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 43:2169-2179. doi: 10.1016/j.molimm.2006.01.005
14. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071:10-23. doi: 10.1016/j.brainres.2005.11.035
15. Gupta S, Grieco MH, Cushman P (1974) Impairment of rosette-forming T lymphocytes in chronic marihuana smokers. N Engl J Med 291:874-877. doi: 10.1056/NEJM197410242911704
16. Heeger PS (2003) T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant 3:525-533. doi: 10.1034/j.1600-6143.2003. 00123.x
17. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583
18. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202. doi: 10.1124/pr.54.2.161
19. Hoyer FF, Steinmetz M, Zimmer S, Becker A, Lutjohann D, Buchalla R, Zimmer A, Nickenig G (2011) Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 51:1007-1014. doi: 10.1016/j.yjmcc.2011.08.008
20. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39:3875-3877. doi: 10.1021/jm960394y
21. 8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7:2905-2914. doi: 10.1016/S0968-0896(99)00219-9
22. Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, Thompson AL, Bushell S, Tartal C, Hurst DP, Reggio PH, Selley DE, Cassidy MP, Wiley JL, Martin BR (2005) Structure-activity relationships for 1-alkyl-3-(1-naphthoyl) indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem 13:89-112. doi: 10.1016/j.bmc.2004.09.050
23. Ihenetu K, Molleman A, Parsons M, Whelan C (2003) Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Eur J Pharmacol 464:207-215. doi: 10.1016/S0014-2999(03)01379-7
24. 9-THC). Res Commun Chem Pathol Pharmacol 7:613-616
25. Kandaswamy R, Stock PG, Skeans MA, Gustafson SK, Sleeman EF, Wainright JL, Carrico RJ, Ghimire V, Snyder JJ, Israni AK, Kasiske BL (2013) OPTN/SRTR 2011 annual data report: pancreas. Am J Transplant 13:47-72. doi: 10.1111/ajt.12020
26. Kim WR, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, Harper AM, Snyder JJ, Israni AK, Kasiske BL (2013) OPTN/SRTR 2011 annual data report: liver. Am J Transplant 13:73-102. doi: 10.1111/ajt.12021
27. Klein TW, Cabral GA (2006) Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimm Pharmacol 1:50-64. doi: 10.1007/s11481-005-9007-x
28. Klein TW, Newton CA, Widen R, Friedman H (1985) The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. J Immunopharmac 7:451-466. doi: 10.3109/08923978509026487
29. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74:486-496. doi: 10.1189/jlb.0303101
30. Lombard C, Nagarkatti M, Nagarkatti P (2007) CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 122:259-270. doi: 10.1016/j.clim.2006.11.002
31. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nature Med 13:492-497. doi: 10.1038/nm1561
32. Marriott KS, Huffman JW, Wiley JL, Martin BR (2006) Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor. Bioorg Med Chem 14:2386-2397. doi: 10.1016/j.bmc.2005.11.023
33. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564. doi: 10.1038/346561a0
34. McCoy KL, Matveyeva M, Carlisle SJ, Cabral GA (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 289:1620-1625
35. 9-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 302:451-465. doi: 10.1124/jpet.102.033506
36. Merville P (2005) Combating chronic renal allograft dysfunction: optimal immunosuppressive regimens. Drugs 65:615-631. doi: 10.2165/00003495-200565050- 00004
37. Munro S, Thomas KK, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65. doi: 10.1038/365061a0
38. Murikinati S, Jüttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, Ledent C, Zimmer A, Kalinke U, Schwaninger M (2010) Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 24:788-798. doi: 10.1096/fj.09-141275
39. Nagarkatti M, Rieder SA, Hegde VL, Kanada S, Nagarkatti P (2010) Do cannabinoids have a therapeutic role in transplantation? Trends Pharmacol Sci 31:345-350. doi: 10.1016/j.tips.2010.05.006
40. Nahas GG, Suciu-Foca N, Armand JP, Morishima A (1974) Inhibition of cellular mediated immunity in marihuana smokers. Science 183:419-420. doi: 10.1126/science.183.4123.419
41. Nahas GG, Morishima A, Desoize B (1977) Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed Proc 36:1748-1752
42. 9-tetrahydrocannabinol: effects on cultured human leucocytes. J Clin Pharmacol New Drugs 10:228-230
43. 9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J Neuroimm Pharmacol 4:92-102. doi: 10.1007/s11481-008- 9126-2
44. 9-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells. J Neuroimmune Pharmacol 7:969-980. doi: 10.1007/s11481-012-9390-z
45. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF (2004) Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis mode. Mult Scler 10:158-164. doi: 10.1191/1352458504ms1009oa
46. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103:696-701. doi: 10.1073/pnas.0504187103
47. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z, Tagliaferro PA, Gardner E, Brusco A, Akinshola BE, Liu QR, Chirwa SS, Hope B, Lujilde J, Inada T, Iwasaki S, Macharia D, Teasenfitz L, Arinami T, Uhl GR (2008) Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 1139:434-449. doi: 10.1196/annals.1432.036
48. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Huffman JW, Csiszar A, Ungvari Z, Mackie K, Chatterjee S, Pacher P (2007) CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol 293:H2210-H2218. doi: 10.1152/ajpheart.00688.2007
49. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, Reichenbach N, Krizbai I, Mahedevan A, Zhang M, Tuma R, Son YJ, Persidsky Y (2012) Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 32:4004-4016. doi: 10.1523/JNEUROSCI.4628-11.201
50. Roth MD (2002) Effects of 9-tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids 121:229-239. doi: 10.1016/S0009-3084(02) 00159-7
51. Servettaz A, Kavian N, Nicco C, Deveaux V, Chereau C, Wang A, Zimmer A, Lotersztajn S, Weill B, Batteux F (2010) Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol 177:187-196. doi: 10.2353/ajpath.2010.090763
52. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999
53. Smith JM, Skeans MA, Thompson B, Horslen SP, Edwards EB, Harper AM, Snyder JJ, Israni AK, Kasiske BL (2013) OPTN/SRTR 2011 annual data report: intestine. Am J Transplant 13:103-118. doi: 10.1111/ajt.12022
54. 9- tetrahydrocannabinol. J Leukoc Biol 84:1574-1584. doi: 10.1189/jlb.0508282
55. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA (2009) Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 15:1678-1685. doi: 10.1002/ibd.20960
56. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M (2004) A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 50:985-998. doi: 10.1002/art.20050
57. Tschöp J, Kasten KR, Nogueiras R, Goetzman HS, Cave CM, England LG, Dattilo J, Lentsch AB, Tschöp MH, Caldwell CC (2009) The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol 183:499-505. doi: 10.4049/jimmunol.0900203
58. Valapour M, Paulson K, Smith JM, Hertz MI, Skeans MA, Heubner BM, Edwards LB, Snyder JJ, Israni AK, Kasiske BL (2013) OPTN/SRTR 2011 annual data report: lung. Am J Transplant 13:149-177. doi: 10.1111/ajt.12024
59. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Patel KD, Sharkey KA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 3100:329-332. doi: 10.1126/science.1115740
60. Waksman Y, Olson JM, Carlisle SJ, Cabral GA (1999) The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 288:1357-1366
61. Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, Razdan RK, Martin BR (2002) Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther 301:679-689. doi: 10.1124/jpet.301.2.679
62. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, Yang HJ, Bi GH, Li J, Gardner EL (2011) Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat Neurosci 14:1160-1166. doi: 10.1038/nn.2874
63. Xu H, Cheng CL, Chen M, Manivannan A, Cabay L, Pertwee RG, Coutts A, Forrester JV (2007) Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 82:532-541. doi: 10.1189/jlb.0307159
64. 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 133:124-131. doi: 10.1016/S0165-5728(02) 00370-3
65. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF (2007) Cannabinoid CB2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27:1387-1396. doi: 10.1038/sj.jcbfm.9600447
66. Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, Tuma RF (2009a) CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res 78:86-94. doi: 10.1016/j.mvr.2009.03. 005
67. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D, Tuma RF (2009b) Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimm Pharmacol 4:249-259. doi: 10.1007/s11481-009-9148-4
68. 9-tetrahydrocannabinol (THC) decreases the number of high and intermediate affinity IL-2 receptors of the IL-2 dependent cell line NKB61A2. Int J Immunopharmacol 15:401-408. doi: 10.1016/0192-0561(93)90051-Y
69. 9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165:373-380